We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 17, 2021

Tafasitamab in Patients With Relapsed/Refractory B–Precursor Cell ALL



Additional Info

A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia
Cancer 2021 Nov 15;127(22)4190-4197, RB Klisovic, WH Leung, W Brugger, M Dirnberger-Hertweck, M Winderlich, SV Ambarkhane, EJ Jabbour

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading